Arvinas, Palleon founders extend the reach of targeted degraders
How ENDTACs and LYTACs expand the reach of targeted protein degradation
A study from Arvinas founder Craig Crews is the second report in as many months of a technology geared to degrade extracellular proteins. The platforms open up new territory for targeted degradation therapies, on the heels of the modality's clinical debut.
In a Thursday ACS Central Science article, Crews' lab at Yale University introduced